{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T03:08:08Z","timestamp":1768014488324,"version":"3.49.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,12,18]],"date-time":"2012-12-18T00:00:00Z","timestamp":1355788800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1038\/nrneph.2012.281","type":"journal-article","created":{"date-parts":[[2012,12,18]],"date-time":"2012-12-18T04:44:19Z","timestamp":1355805859000},"page":"112-121","source":"Crossref","is-referenced-by-count":53,"title":["Improving the efficacy of RAAS blockade in patients with chronic kidney disease"],"prefix":"10.1038","volume":"9","author":[{"given":"Hiddo J.","family":"Lambers Heerspink","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin H.","family":"de Borst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan J. L.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerjan J.","family":"Navis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,18]]},"reference":[{"key":"BFnrneph2012281_CR1","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. Standards of medical care in diabetes--2012. Diabetes Care 35 (Suppl. 1), S11\u2013S63 (2012).","DOI":"10.2337\/dc12-s011"},{"key":"BFnrneph2012281_CR2","doi-asserted-by":"crossref","unstructured":"Kidney Disease Outcomes Quality Initiative. Clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am. J. Kidney Dis. 43 (Suppl. 1), S1\u2013S290 (2004).","DOI":"10.1053\/j.ajkd.2004.03.003"},{"key":"BFnrneph2012281_CR3","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1681\/ASN.2008040416","volume":"20","author":"E Burgess","year":"2009","unstructured":"Burgess, E. et al. Supramaximal dose of candesartan in proteinuric renal disease. J. Am. Soc. Nephrol. 20, 893\u2013900 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012281_CR4","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/HJH.0b013e328332bd61","volume":"28","author":"MR Weir","year":"2010","unstructured":"Weir, M. R. et al. Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria. J. Hypertens. 28, 186\u2013193 (2010).","journal-title":"J. Hypertens."},{"key":"BFnrneph2012281_CR5","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/ki.1989.190","volume":"36","author":"JE Heeg","year":"1989","unstructured":"Heeg, J. E., de Jong, P. E., van der Hem, G. K. & de Zeuuw, D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int. 36, 272\u2013279 (1989).","journal-title":"Kidney Int."},{"key":"BFnrneph2012281_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","volume":"148","author":"R Kunz","year":"2008","unstructured":"Kunz, R., Friedrich, C., Wolbers, M. & Mann, J. F. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann. Intern. Med. 148, 30\u201348 (2008).","journal-title":"Ann. Intern. Med."},{"key":"BFnrneph2012281_CR7","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/j.1464-5491.2007.02097.x","volume":"24","author":"DL Jennings","year":"2007","unstructured":"Jennings, D. L., Kalus, J. S., Coleman, C. I., Manierski, C. & Yee, J. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet. Med. 24, 486\u2013493 (2007).","journal-title":"Diabet. Med."},{"key":"BFnrneph2012281_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1053\/j.ajkd.2006.04.077","volume":"48","author":"M MacKinnon","year":"2006","unstructured":"MacKinnon, M. et al. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am. J. Kidney Dis. 48, 8\u201320 (2006).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2012281_CR9","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1046\/j.1523-1755.2002.00536.x","volume":"62","author":"GD Laverman","year":"2002","unstructured":"Laverman, G. D., Navis, G., Henning, R. H., de Jong, P. E. & de Zeeuw, D. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int. 62, 1020\u20131025 (2002).","journal-title":"Kidney Int."},{"key":"BFnrneph2012281_CR10","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1093\/ndt\/gfp776","volume":"25","author":"VL Esnault","year":"2010","unstructured":"Esnault, V. L., Ekhlas, A., Nguyen, J. M. & Moranne, O. Diuretic uptitration with half dose combined ACEI+ARB better decrease proteinuria than combined ACEI+ARB uptitration. Nephrol. Dial. Transplant. 25, 2218\u20132224 (2010).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2012281_CR11","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1097\/HJH.0b013e3283310f92","volume":"27","author":"HJ Lambers-Heerspink","year":"2009","unstructured":"Lambers-Heerspink, H. J., Perkovic V. & de Zeeuw, D. Renal and cardio-protective effects of direct renin inhibition: a systematic literature review. J. Hypertens. 27, 2321\u20132331 (2009).","journal-title":"J. Hypertens."},{"key":"BFnrneph2012281_CR12","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/ndt\/15.5.637","volume":"15","author":"P van Paassen","year":"2000","unstructured":"van Paassen, P., de Zeeuw, D., Navis, G. & de Jong, P. E. Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function. Nephrol. Dial. Transplant. 15, 637\u2013643 (2000).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2012281_CR13","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2337\/dc09-0168","volume":"32","author":"F Persson","year":"2009","unstructured":"Persson, F. et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 32, 1873\u20131879 (2009).","journal-title":"Diabetes Care"},{"key":"BFnrneph2012281_CR14","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","volume":"358","author":"HH Parving","year":"2008","unstructured":"Parving, H. H. et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 358, 2433\u20132446 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012281_CR15","doi-asserted-by":"publisher","first-page":"594","DOI":"10.2174\/157016111796642689","volume":"9","author":"F Waanders","year":"2011","unstructured":"Waanders, F. et al. Aldosterone, from (patho) physiology to treatment in cardiovascular and renal damage. Curr. Vasc. Pharmacol. 9, 594\u2013605 (2011).","journal-title":"Curr. Vasc. Pharmacol."},{"key":"BFnrneph2012281_CR16","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","volume":"63","author":"ER Blasi","year":"2003","unstructured":"Blasi, E. R. et al. Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 63, 1791\u20131800 (2003).","journal-title":"Kidney Int."},{"key":"BFnrneph2012281_CR17","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1161\/HYPERTENSIONAHA.107.091058","volume":"50","author":"M Nagase","year":"2007","unstructured":"Nagase, M. et al. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension 50, 877\u2013883 (2007).","journal-title":"Hypertension"},{"key":"BFnrneph2012281_CR18","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/sj.ki.5002075","volume":"71","author":"AB Kramer","year":"2007","unstructured":"Kramer, A. B., van der Meulen, E. F., Hamming, I., van Goor, H. & Navis, G. Effect of combining ACE inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis. Kidney Int. 71, 417\u2013424 (2007).","journal-title":"Kidney Int."},{"key":"BFnrneph2012281_CR19","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","volume":"28","author":"K Rossing","year":"2005","unstructured":"Rossing, K., Schjoedt, K. J., Smidt, U. M., Boomsma, F. & Parving, H. H. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 28, 2106\u20132112 (2005).","journal-title":"Diabetes Care"},{"key":"BFnrneph2012281_CR20","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","volume":"24","author":"AH van den Meiracker","year":"2006","unstructured":"van den Meiracker, A. H. et al. Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. J. Hypertens. 24, 2285\u20132292 (2006).","journal-title":"J. Hypertens."},{"key":"BFnrneph2012281_CR21","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/sj.ki.5001580","volume":"70","author":"KJ Schjoedt","year":"2006","unstructured":"Schjoedt, K. J. et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 70, 536\u2013542 (2006).","journal-title":"Kidney Int."},{"key":"BFnrneph2012281_CR22","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2215\/CJN.00240106","volume":"1","author":"M Epstein","year":"2006","unstructured":"Epstein, M. et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin. J. Am. Soc. Nephrol. 1, 940\u2013951 (2006).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2012281_CR23","doi-asserted-by":"publisher","unstructured":"Morales, E. et al. Renoprotective effect of mineralocorticoid receptor blockers in patients with proteinuric kidney disease. Nephrol. Dial. Transplant. http:\/\/dx.doi.org\/10.1093\/ndt\/gfs429 .","DOI":"10.1093\/ndt\/gfs429"},{"key":"BFnrneph2012281_CR24","doi-asserted-by":"publisher","first-page":"542","DOI":"10.2215\/CJN.04750908","volume":"4","author":"SD Navaneethan","year":"2009","unstructured":"Navaneethan, S. D., Nigwekar, S. U., Sehgal, A. R. & Strippoli, G. F. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin. J. Am. Soc. Nephrol. 4, 542\u2013551 (2009).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2012281_CR25","unstructured":"Nederlands Trial Register. trialregister.nl [online] , (2012)."},{"key":"BFnrneph2012281_CR26","doi-asserted-by":"crossref","unstructured":"ONTARGET Investigators et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547\u20131559 (2008).","DOI":"10.1056\/NEJMoa0801317"},{"key":"BFnrneph2012281_CR27","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","volume":"372","author":"JF Mann","year":"2008","unstructured":"Mann, J. F. et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372, 547\u2013553 (2008).","journal-title":"Lancet"},{"key":"BFnrneph2012281_CR28","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nrneph.2009.109","volume":"5","author":"P Ruggenenti","year":"2009","unstructured":"Ruggenenti, P. & Remuzzi, G. Proteinuria: Is the ONTARGET renal substudy actually off target? Nat. Rev. Nephrol. 5, 436\u2013437 (2009).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrneph2012281_CR29","doi-asserted-by":"publisher","first-page":"c137","DOI":"10.1159\/000315882","volume":"116","author":"HJ Lambers-Heerspink","year":"2010","unstructured":"Lambers-Heerspink, H. J. & de Zeeuw, D. Dual RAS therapy not on target, but fully alive. Nephron Clin. Pract. 116, c137\u2013c142 (2010).","journal-title":"Nephron Clin. Pract."},{"key":"BFnrneph2012281_CR30","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1161\/CIRCULATIONAHA.110.964171","volume":"123","author":"SW Tobe","year":"2011","unstructured":"Tobe, S. W. et al. Cardiovascular and renal outcomes with telmisartan, ramipril or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation 123, 1098\u20131107 (2011).","journal-title":"Circulation"},{"key":"BFnrneph2012281_CR31","doi-asserted-by":"publisher","unstructured":"Parving, H. H. et al. Cardio-renal endpoints in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. http:\/\/dx.doi.org\/10.1056\/NEJMoa1208799 .","DOI":"10.1056\/NEJMoa1208799"},{"key":"BFnrneph2012281_CR32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1177\/1470320311434818","volume":"13","author":"HH Parving","year":"2012","unstructured":"Parving, H. H. et al. Baseline characteristics in the aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE). J. Renin Angiotensin Aldosterone Syst. 13, 387\u2013393 (2012).","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"BFnrneph2012281_CR33","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2215\/CJN.03350708","volume":"4","author":"LF Fried","year":"2009","unstructured":"Fried, L. F. et al. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin. J. Am. Soc. Nephrol. 4, 361\u2013368 (2009).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2012281_CR34","first-page":"646","volume":"20","author":"A Maione","year":"2007","unstructured":"Maione, A. et al. Protocol of the long-term impact of RAS inhibition on cardiorenal outcomes (LIRICO) randomized trial. J. Nephrol. 20, 646\u2013655 (2007).","journal-title":"J. Nephrol."},{"key":"BFnrneph2012281_CR35","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2215\/CJN.04310709","volume":"5","author":"AB Chapman","year":"2010","unstructured":"Chapman, A. B. et al. The HALT polycystic kidney disease trials: design and implementation. Clin. J. Am. Soc. Nephrol. 5, 102\u2013109 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2012281_CR36","first-page":"S37","volume":"12","author":"RT Gansevoort","year":"1994","unstructured":"Gansevoort, R. T., de Zeeuw, D., Shahinfar, S., Redfield, A. & de Jong, P. E. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J. Hypertens. Suppl. 12, S37\u2013S42 (1994).","journal-title":"J. Hypertens. Suppl."},{"key":"BFnrneph2012281_CR37","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00125-010-1922-6","volume":"54","author":"Y Miao","year":"2011","unstructured":"Miao, Y. et al. Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia 54, 44\u201350 (2011).","journal-title":"Diabetologia"},{"key":"BFnrneph2012281_CR38","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1093\/ndt\/gfq149","volume":"25","author":"MC Slagman","year":"2010","unstructured":"Slagman, M. C. et al. Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function. Nephrol. Dial. Transplant. 25, 3256\u20133260 (2010).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2012281_CR39","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/sj.ki.5002746","volume":"73","author":"A Mohanram","year":"2008","unstructured":"Mohanram, A., Zhang, Z., Shahinfar, S., Lyle, P. A. & Toto, R. D. The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes. Kidney Int. 73, 630\u2013636 (2008).","journal-title":"Kidney Int."},{"key":"BFnrneph2012281_CR40","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1161\/HYPERTENSIONAHA.111.171488","volume":"58","author":"Y Miao","year":"2011","unstructured":"Miao, Y. et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension 58, 2\u20137 (2011).","journal-title":"Hypertension"},{"key":"BFnrneph2012281_CR41","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1097\/HJH.0b013e32835200f9","volume":"30","author":"PA Smink","year":"2012","unstructured":"Smink, P. A. et al. An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials. J. Hypertens. 30, 1022\u20131028 (2012).","journal-title":"J. Hypertens."},{"key":"BFnrneph2012281_CR42","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.2215\/CJN.08190910","volume":"6","author":"MC Slagman","year":"2011","unstructured":"Slagman, M. C. et al. Effects of antiproteinuric intervention on elevated connective tissue growth factor (CTGF\/CCN-2) plasma and urine levels in nondiabetic nephropathy. Clin. J. Am. Soc. Nephrol. 6, 1845\u20131850 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2012281_CR43","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s11255-007-9299-2","volume":"40","author":"MA Onuigbo","year":"2008","unstructured":"Onuigbo, M. A. & Onuigbo, N. T. Late-onset renal failure from angiotensin blockade (LORFFAB) in 100 CKD patients. Int. Urol. Nephrol. 40, 233\u2013239 (2008).","journal-title":"Int. Urol. Nephrol."},{"key":"BFnrneph2012281_CR44","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/qjmed\/hcn039","volume":"101","author":"MA Onuigbo","year":"2008","unstructured":"Onuigbo, M. A. & Onuigbo, N. T. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis. QJM 101, 519\u2013527 (2008).","journal-title":"QJM"},{"key":"BFnrneph2012281_CR45","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.4065\/83.12.1412-a","volume":"83","author":"MA Onuigbo","year":"2008","unstructured":"Onuigbo, M. A. Radiographic contrast-induced nephropathy and patient mortality. Mayo Clin. Proc. 83, 1412\u20131413 (2008).","journal-title":"Mayo Clin. Proc."},{"key":"BFnrneph2012281_CR46","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/00004872-200403000-00026","volume":"22","author":"C Richer-Giudicelli","year":"2004","unstructured":"Richer-Giudicelli, C. et al. Haemodynamic effects of dual blockade of the renin-angiotensin system in spontaneously hypertensive rats: influence of salt. J. Hypertens. 22, 619\u2013627 (2004).","journal-title":"J. Hypertens."},{"key":"BFnrneph2012281_CR47","doi-asserted-by":"publisher","first-page":"d4366","DOI":"10.1136\/bmj.d4366","volume":"343","author":"MC Slagman","year":"2011","unstructured":"Slagman, M. C. et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ 343, d4366 (2011).","journal-title":"BMJ"},{"key":"BFnrneph2012281_CR48","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1161\/CIRCULATIONAHA.107.703579","volume":"118","author":"BK Nallamothu","year":"2008","unstructured":"Nallamothu, B. K., Hayward, R. A. & Bates, E. R. Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies. Circulation 118, 1294\u20131303 (2008).","journal-title":"Circulation"},{"key":"BFnrneph2012281_CR49","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861\u2013869 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012281_CR50","doi-asserted-by":"crossref","unstructured":"The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349, 1857\u20131863 (1997).","DOI":"10.1016\/S0140-6736(96)11445-8"},{"key":"BFnrneph2012281_CR51","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1097\/00005344-198706000-00016","volume":"9","author":"G Navis","year":"1987","unstructured":"Navis, G., de Jong, P., Donker, A. J., van der Hem G. K. & de Zeeuw, D. Diuretic effects of angiotensin-converting enzyme inhibition: comparison of low and liberal sodium diet in hypertensive patients. J. Cardiovasc. Pharmacol. 9, 743\u2013748 (1987).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"BFnrneph2012281_CR52","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/ki.1987.71","volume":"31","author":"G Navis","year":"1987","unstructured":"Navis, G., de Jong, P. E., Donker, A. J., van der Hem, G. K. & de Zeeuw, D. Moderate sodium restriction in hypertensive subjects: renal effects of ACE-inhibition. Kidney Int. 31, 815\u2013819 (1987).","journal-title":"Kidney Int."},{"key":"BFnrneph2012281_CR53","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/bmj.294.6571.531","volume":"294","author":"GA MacGregor","year":"1987","unstructured":"MacGregor, G. A. et al. Moderate sodium restriction with angiotensin converting enzyme inhibitor in essential hypertension: a double blind study. Br. Med. J. (Clin. Res. Ed.) 294, 531\u2013534 (1987).","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"BFnrneph2012281_CR54","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2337\/diacare.25.4.663","volume":"25","author":"CA Houlihan","year":"2002","unstructured":"Houlihan, C. A. et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care 25, 663\u2013671 (2002).","journal-title":"Diabetes Care"},{"key":"BFnrneph2012281_CR55","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.2337\/dc08-2297","volume":"32","author":"EI Ekinci","year":"2009","unstructured":"Ekinci, E. I. et al. Effects of salt supplementation on the albuminuric response to telmisartan with or without hydrochlorothiazide therapy in hypertensive patients with type 2 diabetes are modulated by habitual dietary salt intake. Diabetes Care 32, 1398\u20131403 (2009).","journal-title":"Diabetes Care"},{"key":"BFnrneph2012281_CR56","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1042\/cs0900393","volume":"90","author":"FH Wapstra","year":"1996","unstructured":"Wapstra, F. H., Van Goor, H., Navis, G., de Jong, P. E. & de Zeeuw, D. Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis. Clin. Sci. (Lond.) 90, 393\u2013401 (1996).","journal-title":"Clin. Sci. (Lond.)"},{"key":"BFnrneph2012281_CR57","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1681\/ASN.2007060693","volume":"19","author":"L Vogt","year":"2008","unstructured":"Vogt, L., Waanders, F., Boomsma, F., de Zeeuw, D. & Navis, G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J. Am. Soc. Nephrol. 19, 999\u20131007 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012281_CR58","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1177\/1074248410377173","volume":"15","author":"MR Weir","year":"2010","unstructured":"Weir, M. R., Yadao, A. M., Purkayastha, D. & Charney, A. N. Effects of high- and low-sodium diets on ambulatory blood pressure in patients with hypertension receiving aliskiren. J. Cardiovasc. Pharmacol. Ther. 15, 356\u2013363 (2010).","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"BFnrneph2012281_CR59","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1093\/ndt\/13.7.1682","volume":"13","author":"H Buter","year":"1998","unstructured":"Buter, H., Hemmelder, M. H., Navis, G., de Jong, P. E. & de Zeeuw, D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol. Dial. Transplant. 13, 1682\u20131685 (1998).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2012281_CR60","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","volume":"354","author":"P Ruggenenti","year":"1999","unstructured":"Ruggenenti, P. et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354, 359\u2013364 (1999).","journal-title":"Lancet"},{"key":"BFnrneph2012281_CR61","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1681\/ASN.2011040430","volume":"23","author":"S Vegter","year":"2011","unstructured":"Vegter, S. et al. Sodium intake, ACE inhibition, and progression to ESRD. J. Am. Soc. Nephrol. 23, 165\u2013173 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012281_CR62","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ki.2012.74","volume":"82","author":"HJ Lambers-Heerspink","year":"2012","unstructured":"Lambers-Heerspink, H. J. et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int. 82, 330\u2013337 (2012).","journal-title":"Kidney Int."},{"key":"BFnrneph2012281_CR63","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/01.ASN.0000051700.07403.27","volume":"14","author":"V Vallon","year":"2003","unstructured":"Vallon, V., Blantz, R. C. & Thomson, S. Glomerular hyperfiltration and the salt paradox in early [corrected] type 1 diabetes mellitus: a tubulo-centric view. J. Am. Soc. Nephrol. 14, 530\u2013537 (2003).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012281_CR64","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00125-001-0763-8","volume":"45","author":"PT Luik","year":"2002","unstructured":"Luik, P. T. et al. Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric type I diabetes mellitus. Diabetologia 45, 535\u2013541 (2002).","journal-title":"Diabetologia"},{"key":"BFnrneph2012281_CR65","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1136\/bmj.39147.604896.55","volume":"334","author":"NR Cook","year":"2007","unstructured":"Cook, N. R. et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 334, 885\u2013888 (2007).","journal-title":"BMJ"},{"key":"BFnrneph2012281_CR66","doi-asserted-by":"publisher","unstructured":"Taylor, R. S., Ashton, K. E., Moxham, T., Hooper, L. & Ebrahim, S. Reduced dietary salt for the prevention of cardiovascular disease. Cochrane Database of Systematic Reviews, Issue 7. Art. No.: CD009217. http:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/14651858.CD009217\/ .","DOI":"10.1002\/14651858.CD009217\/"},{"key":"BFnrneph2012281_CR67","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S0140-6736(11)61174-4","volume":"378","author":"FJ He","year":"2011","unstructured":"He, F. J. & MacGregor, G. A. Salt reduction lowers cardiovascular risk: meta-analysis of outcome trials. Lancet 378, 380\u2013382 (2011).","journal-title":"Lancet"},{"key":"BFnrneph2012281_CR68","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1042\/CS20070193","volume":"114","author":"S Paterna","year":"2008","unstructured":"Paterna, S., Gaspare, P., Fasullo, S., Sarullo, F. M. & di Pasquale, P. Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend? Clin. Sci. (Lond.) 114, 221\u2013230 (2008).","journal-title":"Clin. Sci. (Lond.)"},{"key":"BFnrneph2012281_CR69","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/01.hjh.0000160217.86597.b6","volume":"23","author":"MJ Kocks","year":"2005","unstructured":"Kocks, M. J., Lely, A. T., Boomsma, F., de Jong, P. E. & Navis, G. Sodium status and angiotensin-converting enzyme inhibition: effects on plasma angiotensin(1\u20137) in healthy man. J. Hypertens. 23, 597\u2013602 (2005).","journal-title":"J. Hypertens."},{"key":"BFnrneph2012281_CR70","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1097\/00005344-200311000-00004","volume":"42","author":"MJ Kocks","year":"2003","unstructured":"Kocks, M. J. et al. High dietary sodium blunts affects of angiotensin-converting enzyme inhibition on vascular angiotensin I-to-angiotensin II conversion in rats. J. Cardiovasc. Pharmacol. 42, 601\u2013606 (2003).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"BFnrneph2012281_CR71","first-page":"395","volume":"95","author":"L Vogt","year":"2004","unstructured":"Vogt, L., Kocks, M. J., Laverman, G. D. & Navis, G. Renoprotection by blockade of the renin\u2013angiotensin\u2013aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance? Minerva Med. 95, 395\u2013409 (2004).","journal-title":"Minerva Med."},{"key":"BFnrneph2012281_CR72","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/path.1956","volume":"209","author":"I Hamming","year":"2006","unstructured":"Hamming, I., Navis, G., Kocks, M. J. & van Goor, H. ACE inhibition has adverse renal effects during dietary sodium restriction in proteinuric and healthy rats. J. Pathol. 209, 129\u2013139 (2006).","journal-title":"J. Pathol."},{"key":"BFnrneph2012281_CR73","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3317\/jraas.2003.035","volume":"4","author":"P Trongtorsak","year":"2003","unstructured":"Trongtorsak, P., Morgan, T. O. & Delbridge, L. M. Combined renin-angiotensin system blockade and dietary sodium restriction impairs cardiomyocyte contractility. J. Renin Angiotensin Aldosterone Syst. 4, 213\u2013219 (2003).","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"BFnrneph2012281_CR74","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2337\/dc10-1722","volume":"34","author":"MC Thomas","year":"2011","unstructured":"Thomas, M. C. et al. The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes. Diabetes Care 34, 861\u2013866 (2011).","journal-title":"Diabetes Care"},{"key":"BFnrneph2012281_CR75","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1001\/jama.2011.1729","volume":"306","author":"MJ O'Donnell","year":"2011","unstructured":"O'Donnell, M. J. et al. Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA 306, 2229\u20132238 (2011).","journal-title":"JAMA"},{"key":"BFnrneph2012281_CR76","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2337\/dc10-1723","volume":"34","author":"EI Ekinci","year":"2011","unstructured":"Ekinci, E. I. et al. Dietary salt intake and mortality in patients with type 2 diabetes. Diabetes Care 34, 703\u2013709 (2011).","journal-title":"Diabetes Care"},{"key":"BFnrneph2012281_CR77","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/oby.2009.61","volume":"17","author":"FW Visser","year":"2009","unstructured":"Visser, F. W., Krikken, J. A., Muntinga, J. H., Dierckx, R. A. & Navis, G. J. Rise in extracellular fluid volume during high sodium depends on BMI in healthy men. Obesity (Silver Spring) 17, 1684\u20131688 (2009).","journal-title":"Obesity (Silver Spring)"},{"key":"BFnrneph2012281_CR78","doi-asserted-by":"publisher","first-page":"e1001177","DOI":"10.1371\/journal.pgen.1001177","volume":"6","author":"S Padmanabhan","year":"2010","unstructured":"Padmanabhan, S. et al. Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. PLoS Genet. 6, e1001177 (2010).","journal-title":"PLoS Genet."},{"key":"BFnrneph2012281_CR79","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1093\/ndt\/gfr408","volume":"27","author":"MC Slagman","year":"2012","unstructured":"Slagman, M. C. et al. Elevated N-terminal pro-brain natriuretic peptide levels predict an enhanced anti-hypertensive and anti-proteinuric benefit of dietary sodium restriction and diuretics, but not angiotensin receptor blockade, in proteinuric renal patients. Nephrol. Dial. Transplant. 27, 983\u2013990 (2012).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2012281_CR80","first-page":"S23","volume":"63","author":"FG van der Kleij","year":"1997","unstructured":"van der Kleij, F. G. et al. Angiotensin converting enzyme insertion\/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status. Kidney Int. Suppl. 63, S23\u2013S26 (1997).","journal-title":"Kidney Int. Suppl."},{"key":"BFnrneph2012281_CR81","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1097\/HJH.0b013e32833eaf34","volume":"28","author":"TA Lely","year":"2010","unstructured":"Lely, T. A. et al. Response to angiotensin-converting enzyme inhibition is selectively blunted by high sodium in angiotensin-converting enzyme DD genotype: evidence for gene-environment interaction in healthy volunteers. J. Hypertens. 28, 2414\u20132421 (2010).","journal-title":"J. Hypertens."},{"key":"BFnrneph2012281_CR82","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/MNH.0b013e3283312fc8","volume":"18","author":"JA Krikken","year":"2009","unstructured":"Krikken, J. A., Laverman, G. D. & Navis, G. Benefits of dietary sodium restriction in the management of chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 18, 531\u2013538 (2009).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"BFnrneph2012281_CR83","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1093\/ndt\/gfs069","volume":"27","author":"E van den Berg","year":"2012","unstructured":"van den Berg, E. et al. Sodium intake and blood pressure in renal transplant recipients. Nephrol. Dial. Transplant. 27, 3352\u20133359 (2012).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2012281_CR84","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","volume":"376","author":"D de Zeeuw","year":"2010","unstructured":"de Zeeuw, D. et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 376, 1543\u20131551 (2010).","journal-title":"Lancet"},{"key":"BFnrneph2012281_CR85","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nrneph.2009.185","volume":"5","author":"CR Doorenbos","year":"2009","unstructured":"Doorenbos, C. R., van den Born, J., Navis, G. & de Borst, M. H. Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism. Nat. Rev. Nephrol. 5, 691\u2013700 (2009).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrneph2012281_CR86","unstructured":"Nederlands Trial Register. trialregister.nl [online] , (2012)."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2012.281.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2012.281","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2012.281.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:39:29Z","timestamp":1684471169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2012.281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,18]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["BFnrneph2012281"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2012.281","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,18]]}}}